fluselenamyl

Fluselenamyl is an investigational positron emission tomography (PET) radiotracer developed by the Washington University School of Medicine. It is a selenium-containing small molecule labeled with the radioisotope fluorine-18 ([18F]), specifically designed to bind to amyloid fibrils. The agent is primarily being evaluated for the noninvasive detection and characterization of amyloid deposits in the heart, which is critical for the diagnosis and management of cardiac amyloidosis. By targeting the misfolded protein aggregates that define the pathology, fluselenamyl aims to provide high-contrast imaging to distinguish amyloidosis from other forms of cardiomyopathy and potentially monitor disease progression or therapeutic response.

Other names

Fluselenamyl[18F]-Fluselenamyl